|
|
Volumn 16, Issue 1, 2015, Pages 57-59
|
|
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: Treatment rationale and protocol dynamics of the METAL trial
a
a
a
a
a
a
a
a
|
|
Author keywords
2 Part trial; EGFR tyrosine kinase inhibitors; Erlotinib; Metformin; NSCLC; Recurrent
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
K RAS PROTEIN;
METFORMIN;
VASCULOTROPIN;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
ADULT;
ADVANCED CANCER;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER GROWTH;
CANCER PATIENT;
CANCER STAGING;
DRUG DOSE ESCALATION;
DRUG DOSE INCREASE;
DRUG IDENTIFICATION;
DRUG MEGADOSE;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
EXON;
FOLLOW UP;
GENE AMPLIFICATION;
HUMAN;
MAJOR CLINICAL STUDY;
MAXIMUM TOLERATED DOSE;
MULTICENTER STUDY;
NON SMALL CELL LUNG CANCER;
OPEN STUDY;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL;
QUALITY OF LIFE;
RECOMMENDED DRUG DOSE;
STUDY DESIGN;
UNSPECIFIED SIDE EFFECT;
AGED;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DOSE CALCULATION;
FEMALE;
LUNG NEOPLASMS;
MALE;
METHODOLOGY;
MIDDLE AGED;
MORTALITY;
TREATMENT OUTCOME;
VERY ELDERLY;
YOUNG ADULT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL PROTOCOLS;
DISEASE-FREE SURVIVAL;
DRUG DOSAGE CALCULATIONS;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
METFORMIN;
MIDDLE AGED;
NEOPLASM STAGING;
QUINAZOLINES;
RESEARCH DESIGN;
TREATMENT OUTCOME;
YOUNG ADULT;
|
|
EID: 84927520355
PISSN: 15257304
EISSN: 19380690
Source Type: Journal
DOI: 10.1016/j.cllc.2014.06.010 Document Type: Article |
|
Times cited : (17)
|
|
References (15)
|
